The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non–small cell lung cancer.
 
Yuankai Shi
No Relationships to Disclose
 
Jianhua Chen
No Relationships to Disclose
 
Helong Zhang
No Relationships to Disclose
 
Zhihong Zhang
No Relationships to Disclose
 
Yiping Zhang
No Relationships to Disclose
 
Zhehai Wang
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Shucai Zhang
No Relationships to Disclose
 
Jian Zhao
No Relationships to Disclose
 
Chunling Liu
No Relationships to Disclose
 
Xiuwen Wang
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Changlu Hu
No Relationships to Disclose
 
Lei Yang
No Relationships to Disclose
 
Xuezhi Hao
No Relationships to Disclose
 
Lin Wang
No Relationships to Disclose
 
Meimei Si
Employment - QiLu Pharmaceutical
 
Mingjing Ge
Employment - QiLu Pharmaceutical
 
Huaize Geng
Employment - QiLu Pharmaceutical